fonsartan

Subscribe to Selected New Research on fonsartan

4 relevant articles (1 outcomes, 2 trials/studies) found for this Bio-Agent

Description: an angiotensin II receptor antagonist; structure given in first source

Also Known As:

(imidazolylbiphenylyl)sulfonylurea; HR 720; HR-720; fon-sartan; 2-butyl-4-(methylthio)-1-((2'-((((propylamino)carbonyl)amino)sulfonyl)(1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-carboxylic acid dipotassium salt

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Biphenyl Compounds: 1

fonsartan: 4

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Imidazoles: 94

fonsartan: 4

Related Diseases

1.	Cardiomegaly (Heart Hypertrophy) 01/01/2001 - "RESULTS: Fonsartan (HR720) treatment attenuated cardiac hypertrophy when treatment started 30 min or later after MI, limited infarct size when treatment initiated 3 and 24 h after MI, decreased left ventricular end-diastolic pressure when treatment started 3 h to 7 days after MI, and improved dP/dt(max) when treatment commenced 24 h and 7 days after MI compared to untreated infarct group" Get all the results and reference details, order at left...
2.	Stroke (Strokes) 01/01/1997 - "We evaluated the renal effects of the new angiotensin II type 1 (AT ) receptor antagonist, HR 720, in the stroke-prone spontaneously hypertensive rat" 04/01/2000 - "In this study, we investigated the outcome of lifelong treatment with the angiotensin II type 1 receptor (AT(1)) blocker fonsartan (HR 720) in young stroke-prone spontaneously hypertensive rats (SHR-SP)" Get all the results and reference details, order at left...
3.	Heart Failure 01/01/2001 - "Therefore, the purpose of the present study was to compare the effects of very early (30 min after MI), early (3 and 24 h after MI) and delayed (7 days after MI) treatments with the angiotensin AT(1) receptor antagonist fonsartan (HR 720) on cardiac morphological and hemodynamic parameters in a rat model of MI-induced heart failure and to establish the therapeutic window for the start of treatment" Get all the results and reference details, order at left...
4.	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 04/01/2000 - "After 15 months, a time when approximately 80% of the placebo group had died, left ventricular hypertrophy was completely prevented in fonsartan-treated animals" Get all the results and reference details, order at left...
5.	Ventricular Fibrillation 03/01/2003 - "Treatment with fonsartan and losartan significantly decreased the duration of ventricular fibrillation as compared to L-NAME group" Get all the results and reference details, order at left...
9 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	fonsartan
2.	Type 1 Angiotensin Receptor
3.	Angiotensins
4.	Losartan (Cozaar)
5.	NG-Nitroarginine Methyl Ester (L-NAME)
6.	Angiotensin II
6 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>